- Chemotherapy
- Targeted Therapy
- Hormonal Therapy
- Immunotherapy
- Radiation Therapy
Triple Negative Breast Cancer Market size was valued at USD 1,286.4 million in 2023 and is poised to grow at a CAGR of 4.9% from 2024-2030. Triple Negative Breast Cancer Market is an aggressive form of breast cancer that lacks three essential receptors: estrogenic receptors (ER), progesterone receptors (PR), and human epidermal growth factor 2 (HER2). These receptors play a crucial part in the progression and development of most breast malignancies. TNBC accounts for approximately 15 to 20% of all breast cancer diagnoses, making it a significant concern for the healthcare industry. The triple-negative breast cancer market is substantial due to the limited treatment options for this subtype of breast cancer compared to other subtypes.
In TNBC, conventional hormone therapies and targeted therapies like Herceptin have demonstrated little efficacy indicating the need for new and improved therapy options. Consequently, public and private organizations invest in research and development to discover new treatments and enhance patient outcomes. Growing incidence of triple-negative breast cancer, new and advanced diagnostic procedures, and therapeutic options, increasing awareness and efforts for early detection, increasing research and development efforts, and greater emphasis on personalized medicine are the main driving factors of the triple-negative breast cancer market.
Moreover, lack of biomarkers for patient stratification can impede market growth, adverse reactions arising from breast cancer therapeutics, such as targeted therapies, innovative targeted therapies, and personalized treatment approaches are frequently more expensive than standard chemotherapy, and the variable treatment response observed in TNBC patients for the same drug all adds up to the restraints of the triple-negative breast cancer market. Expanding healthcare infrastructure, increasing awareness in emerging markets, and constant innovations in advanced therapeutics present significant growth opportunities. With the growing trend toward developing targeted therapies and immunotherapies for TNBC cells, AI and machine learning are being increasingly used in research and clinical settings to identify potential drug candidates.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
The prevalence of TNBC has increased significantly worldwide. TNBC is diagnosed more frequently in younger women. The cancer is detected the reoccurrence is high such that at least 40% of patients are reoccurring patients. The overall five-year survival rate for triple-negative breast cancer is 77%. However, when cancer has metastasized, the survival rate drops significantly to 12%. All these gives a significant advantage to the companies to expand it’s market by providing efficient therapy options. The recent approvals of PD-1 inhibitors like KEYTRUDA (pembrolizumab) and PARP inhibitors like LYNPARZA (olaparib) have led to significant improvement of treatment response in certain patients in first-line treatment, while transformative antibody-drug conjugates (ADCs) like TRODELVY (sacituzumab govitecan), which works by TROP2 inhibition, has led to significant improvement of patient prognosis in later lines of treatment. Additionally, the emerging pipeline for TNBC includes several potential drugs like COSELA (trilaciclib), capivasertib, and datopotamab deruxtecan (Dato-DXd) indicating the constant advancement in research and innovation in this market. This also indicates substantial funding from public and private organizations. All these factors added up, driving the market to expansion.
The Triple Negative Breast Cancer Market size was valued at USD 1,286.4 million in 2023 and is poised to grow at a CAGR of 4.9% from 2024-2030.
Major companies operating within the Triple Negative Breast Cancer Market are F. Hoffmann-La Roche Ltd, AstraZeneca, Pfizer Inc., and Novartis AG
Rising incidence of TNBC, advancements in research and development, government and private funding, increasing awareness of the disease, development of new and precise therapies such as immunotherapy, and hormonal therapy and Advances in diagnostic techniques have led to early detection are the main drivers of the Triple-Negative Breast Cancer market.
North America, particularly the United States, leads in the Triple Negative Breast Cancer Market due to the prevalence of the presence of disease, research institutions, universities, and biotechnology companies with significant investments in R&D activities
1.Executive Summary |
2.Global Triple Negative Breast Cancer Market Introduction |
2.1.Global Triple Negative Breast Cancer Market - Taxonomy |
2.2.Global Triple Negative Breast Cancer Market - Definitions |
2.2.1.Treatment Type |
2.2.2.Drug Class |
2.2.3. Route of Administration |
2.2.4.Distribution Channel |
2.2.5.Region |
3.Global Triple Negative Breast Cancer Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Triple Negative Breast Cancer Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Triple Negative Breast Cancer Market By Treatment Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. Chemotherapy |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Targeted Therapy |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Hormonal Therapy |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Immunotherapy |
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Radiation Therapy |
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
6.Global Triple Negative Breast Cancer Market By Drug Class, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. Doxorubicin |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Cyclophosphamide |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Paclitaxel |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Docetaxel |
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
6.5. Cisplatin/Carboplatin |
6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.5.3. Market Opportunity Analysis |
6.6. Other Drug Types |
6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.6.3. Market Opportunity Analysis |
7.Global Triple Negative Breast Cancer Market By Route of Administration, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. Oral |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Parenteral |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Others |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8.Global Triple Negative Breast Cancer Market By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. Hospital Pharmacies |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Retail Pharmacies |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Online Pharmacies |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
9.Global Triple Negative Breast Cancer Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. North America |
9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.1.3. Market Opportunity Analysis |
9.2. Europe |
9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.2.3. Market Opportunity Analysis |
9.3. Asia Pacific (APAC) |
9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.3.3. Market Opportunity Analysis |
9.4. Middle East and Africa (MEA) |
9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.4.3. Market Opportunity Analysis |
9.5. Latin America |
9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.5.3. Market Opportunity Analysis |
10.North America Triple Negative Breast Cancer Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. Treatment Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Chemotherapy |
10.1.2.Targeted Therapy |
10.1.3.Hormonal Therapy |
10.1.4.Immunotherapy |
10.1.5.Radiation Therapy |
10.2. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Doxorubicin |
10.2.2.Cyclophosphamide |
10.2.3.Paclitaxel |
10.2.4.Docetaxel |
10.2.5.Cisplatin/Carboplatin |
10.2.6.Other Drug Types |
10.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Oral |
10.3.2.Parenteral |
10.3.3.Others |
10.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Hospital Pharmacies |
10.4.2.Retail Pharmacies |
10.4.3.Online Pharmacies |
10.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.5.1.United States of America (USA) |
10.5.2.Canada |
11.Europe Triple Negative Breast Cancer Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Chemotherapy |
11.1.2.Targeted Therapy |
11.1.3.Hormonal Therapy |
11.1.4.Immunotherapy |
11.1.5.Radiation Therapy |
11.2. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Doxorubicin |
11.2.2.Cyclophosphamide |
11.2.3.Paclitaxel |
11.2.4.Docetaxel |
11.2.5.Cisplatin/Carboplatin |
11.2.6.Other Drug Types |
11.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Oral |
11.3.2.Parenteral |
11.3.3.Others |
11.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.Hospital Pharmacies |
11.4.2.Retail Pharmacies |
11.4.3.Online Pharmacies |
11.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.5.1.Germany |
11.5.2.France |
11.5.3.Italy |
11.5.4.United Kingdom (UK) |
11.5.5.Spain |
12.Asia Pacific (APAC) Triple Negative Breast Cancer Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Chemotherapy |
12.1.2.Targeted Therapy |
12.1.3.Hormonal Therapy |
12.1.4.Immunotherapy |
12.1.5.Radiation Therapy |
12.2. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Doxorubicin |
12.2.2.Cyclophosphamide |
12.2.3.Paclitaxel |
12.2.4.Docetaxel |
12.2.5.Cisplatin/Carboplatin |
12.2.6.Other Drug Types |
12.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Oral |
12.3.2.Parenteral |
12.3.3.Others |
12.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.Hospital Pharmacies |
12.4.2.Retail Pharmacies |
12.4.3.Online Pharmacies |
12.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.5.1.China |
12.5.2.India |
12.5.3.Australia and New Zealand (ANZ) |
12.5.4.Japan |
12.5.5.Rest of APAC |
13.Middle East and Africa (MEA) Triple Negative Breast Cancer Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
13.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Chemotherapy |
13.1.2.Targeted Therapy |
13.1.3.Hormonal Therapy |
13.1.4.Immunotherapy |
13.1.5.Radiation Therapy |
13.2. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Doxorubicin |
13.2.2.Cyclophosphamide |
13.2.3.Paclitaxel |
13.2.4.Docetaxel |
13.2.5.Cisplatin/Carboplatin |
13.2.6.Other Drug Types |
13.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Oral |
13.3.2.Parenteral |
13.3.3.Others |
13.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Hospital Pharmacies |
13.4.2.Retail Pharmacies |
13.4.3.Online Pharmacies |
13.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.5.1.GCC Countries |
13.5.2.South Africa |
13.5.3.Rest of MEA |
14.Latin America Triple Negative Breast Cancer Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
14.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.1.1.Chemotherapy |
14.1.2.Targeted Therapy |
14.1.3.Hormonal Therapy |
14.1.4.Immunotherapy |
14.1.5.Radiation Therapy |
14.2. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.2.1.Doxorubicin |
14.2.2.Cyclophosphamide |
14.2.3.Paclitaxel |
14.2.4.Docetaxel |
14.2.5.Cisplatin/Carboplatin |
14.2.6.Other Drug Types |
14.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.3.1.Oral |
14.3.2.Parenteral |
14.3.3.Others |
14.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.4.1.Hospital Pharmacies |
14.4.2.Retail Pharmacies |
14.4.3.Online Pharmacies |
14.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.5.1.Brazil |
14.5.2.Mexico |
14.5.3.Rest of LA |
15. Competition Landscape |
15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
15.2.1.Abbott (U.S.) |
15.2.2.AbbVie Inc. (U.S.) |
15.2.3.Amneal Pharmaceuticals LLC. (U.S.) |
15.2.4.Aurobindo Pharma (India) |
15.2.5.Bayer AG (Germany) |
15.2.6.Bristol-Myers Squibb Company (U.S.) |
15.2.7.Cipla Inc. (U.S.) |
15.2.8.GSK plc. (U.K.) |
15.2.9.Hikma Pharmaceuticals PLC (U.K.) |
15.2.10.Johnson & Johnson Private Limited (U.S.) |
15.2.11.Lupin (India) |
15.2.12.Merck KGaA (Germany) |
15.2.13.Mylan N.V. (U.S.) |
15.2.14.Novartis AG (Switzerland) |
15.2.15.Pfizer Inc (U.S.) |
16. Research Methodology |
17. Appendix and Abbreviations |